02-06-2025
Analysts Conflicted on These Healthcare Names: CSPC Pharmaceutical Group (OtherCHJTF) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on CSPC Pharmaceutical Group (CHJTF – Research Report) and Moderna (MRNA – Research Report).
Confident Investing Starts Here:
CSPC Pharmaceutical Group (CHJTF)
Jefferies analyst Chu Wang downgraded CSPC Pharmaceutical Group to Sell yesterday and set a price target of HK$5.00. The company's shares closed last Tuesday at $0.81.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CSPC Pharmaceutical Group with a $0.84 average price target.
Moderna (MRNA)
In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on Moderna. The company's shares closed last Friday at $26.56.
According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences.
Moderna has an analyst consensus of Hold, with a price target consensus of $49.36, implying an 87.4% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
